CDXC logo

ChromaDex Corporation

CDXC

CDXC: ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segment namely Consumer Products, Ingredients segment and Analytical Reference Standards and Services. Majority of the revenue is earned from Consumer Products segment.

more

Show CDXC Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of CDXC by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by CDXC's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development Dec. 13, 2022
  • Patent Title: Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof Mar. 15, 2022
  • Patent Title: Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof Feb. 08, 2022
  • Patent Title: Crystalline forms of nicotinoyl ribosides and derivatives thereof, and methods of preparation thereof Jan. 04, 2022
  • Patent Title: Nicotinamide riboside compositions for topical use in treating skin conditions Jun. 15, 2021
  • Patent Title: B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof Mar. 02, 2021
  • Patent Title: Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development Dec. 08, 2020
  • Patent Title: Nicotinamide riboside compositions for topical use in treating skin conditions Jun. 23, 2020
  • Patent Title: Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions May. 07, 2019
  • Patent Title: Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+ increasing precursors Jan. 22, 2019
  • Patent Title: Method for treating non-melanoma skin cancer by inducing udp-glucuronosyltransferase activity using pterostilbene Aug. 07, 2018
  • Patent Title: B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof Jun. 19, 2018
  • Patent Title: Method for inducing udp-glucuronosyltransferase activity using pterostilbene Sep. 23, 2014
Government Contracts

Federal grants, loans, and purchases

WallStreetBets

Number of mentions of CDXC in WallStreetBets Daily Discussion

CDXC News

Recent insights relating to CDXC

CNBC Recommendations

Recent picks made for CDXC stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CDXC

Corporate Flights

Flights by private jets registered to CDXC